ELSEVIER

Contraception

Contraception 69 (2004) 517–519

Author Index
Volume 69
January–June, 2004

Abramov, Y., 151
Abuabara, K., 339
Agnello, C., 237
Agnihotri, P.K., 379
Aktulay, A., 279
Albright, J., 213
Aldrighi, J.M., 395
Ali, M.M., 15
Allen, A., 137
Alvarez, F., 137
Aranha, C., 333
Archer, D.F., 189
Arévalo, M., 201
Aronsson, A., 165
Arsenijević, S., 327
Ash, A.S., 43
Ashok, P.W., 51

Bahamondes, L., 137, 395
Bairagy, N.R., 47
Barlow, W.E., 99
Bassol, S., 115
Batár, I., 501
Becker, D., 295, 339
Becker, S., 419
Beenhakker, B., 419
Beksinska, M., 3
Bender, S.S., 481
Bereczki, Z., 27
Berenson, A.B., 219, 227
Berlin, J.A., 353
Bernstein, L., 353
Bhaduri, A.P., 379
Bigrigg, A., 133
Bjarnadóttir, R.I., 461
Blanchard, K., 301, 339, 347
Bleau, G., 425
Bley, K., 367
Blum, J., 63
Blumenthal, P., 347, 419
Booranabunyat, S., 489
Botha, J., 3
Brache, V., 137
Buicu, C., 271
Burkman, R.T., 353, 447
Bygdeman, M., 373

Cabral, R., 213
Caetano, M.E., 395
Canto de Cetina, T.E., 115
Canto, J.A C., 115
Cao, L., 505
Cao, X., 207
Caruso, S., 237
Cekan, S.Z., 373
Çelen, Ş., 279
Che, Y., 15
Chélli, H., 63
Cheng, D., 437
Chuang, C.H., 43
Cianci, A., 237
Clark, A., 241
Cleland, J.G., 15
Colm, J., 367
Coyaji, K., 157
Creasy, G.W., 189
Creinin, M.D., 145
Croxatto, H., 137
Cullins, V., 189
Curtis, K.M., 213

Daling, J.R., 353
Danışman, N., 279
Darwish, A., 121
Deapen, D., 353
Dekel, A., 289
Deneux-Tharaux, C., 401
Desager, J.P., 271
di Capua, E., 343
Di Mari, L., 237
Dieben, Th.O.M., 129, 197, 389, 461
Düsterberg, B., 179
Dwivedi, A., 379

Elasy, T.A., 251
Ellertson, C., 77, 157, 295, 301, 339
Endrikat, J., 179, 271
Eurenius, K., 309

Fahim, H.I., 317
Fairhurst, K., 361
Farina, M., 237
Fehring, R.J., 9
Felsenberg, D., 179
Ferguson, H., 469
Fisher, A.C., 189
Flett, G.M.M., 51
Folger, S.G., 353
Foster, A., 77
Freund, K.M., 43
Fulcheri, E., 343
Fung, I., 493

Gadalla, M.A., 317
Gainer, E., 83
Galal, M., 121
Gallagher, J., 133
Gamzu, R., 84
Gao, Y.-T., 251
Garcia, S.G., 295, 339
Gaspard, U., 271
Gaudet, L.M., 31
Geirsson, R.T., 461, 481
Gemzell-Danielsson, K., 165, 373
Gerlinger, C., 179, 271
Gilliam, M., 413
Glasier, A., 301, 361
Golden, M.R., 241
Grimes, D.A., 343
Gross, S., 367
Grossman, D., 77
Grujičić, D., 327
Gu, Z.-P., 505
Gudmundsdóttir, B.R., 461
Gueddana, N., 63
Gupta, S., 333

Hackmon, R., 289
Hagerty, C.G., 447
Hahn, P.M., 31
Hajri, S., 63
Handsfield, H.H., 241
Harrison-Woolrych, M., 83
Hassan, S., 121
Haukkamaa, M., 407
Hedley, A., 157
Heithecker, R., 271
Helmers, J.R., 241
Helström, L., 165
Henchcliffe, B., 301
Henderson, A., 493
Hesketh, C., 133
Hires, S., 419
Hogben, M., 241
Holland, H., 213
Holmes, K.K., 241
Hommel, H.H., 37

0010-7824/04/$ – see front matter © 2004 Elsevier Inc. All rights reserved.

Hubacher, D., 437
Huggins, G., 419
Hunt, J., 301
Hussain, S.F., 89
Hwang, A.C., 1, 87, 177, 261, 345, 433

Ichikawa, L.E., 99
Intelisano, G., 237
Issa, A.H., 317

Jakobsson, T., 407
Janssen, P.A., 493
Jennings, V., 201
Jin, F., 251
Jin, J.-D., 505

Kade, K., 59
Kahn, E., 401
Kaplan, B., 289
Kaunitz, A.M., 267
Kayahan, A., 323
Khella, A.K., 317
King, H., 301
Kiss, E., 27
Kitchlu, S., 379
Kives, S., 31
Klimscheffskij, R., 389
Knight, S., 413
Kohaut, B.A., 267
Kuhl, H., 37
Kulik-Rechberger, B., 477
Kumar, D., 59
Kumar, N., 137

Labeeb, S., 121
LaCroix, A.Z., 99
Laforest, G., 425
Lagro-Janssen, T.L.M., 283
Lai, J.-J., 263
Lakha, F., 361
Lakos, G., 27
Land, K., 179
Larsson, M., 309
Lee, S.S.N., 247
Leng, Y., 505
Li, C., 207
Li, C.-f.I., 247
Li, Q., 251
Lin, N., 207
Loftus-Granberg, B., 133
Lončar, D., 327
Luna, M.O., 115

Magnusdóttir, E.M., 461
Magnusdóttir, S.D., 461
Malhotra, S., 71
Malinski, C., 241
Malone, K.E., 353
Mansour, F.B., 63
Marchbanks, P.A., 353
Marions, L., 373
Martinez, T.R.L., 395
März, W., 105
Massai, R., 137
Mauck, C., 263
McCaig, C., 301
McCarthy, Jr., M., 413
McFadyen, L., 3
Mehrotra, P.K., 379
Méry, C., 83
Mih, E., 179
Miller, K., 347
Milošević-Djordjević, O., 327
Molano Di Targiana, N., 419
Moo-Young, A., 137
Möröy, P., 279
Mulders, J.A.P.A., 469
Mulders, T.M.T., 129
Mullick, B.C., 47
Musselman, B.L., 267

Nadjari, M., 151
Nauck, M., 105
Nazerali, H., 401
Ngoc, N.T.N., 157
Nitke, S., 289
Norman, S.A., 353
Norris Turner, A., 157

Önundarson, P.T., 461
Orbach, D., 171
Ott, S.M., 99

Pandhi, P., 71
Payne, P., 213
Petersen, G., 105
Petersen, R., 213
Petta, C.A., 395
Piepzowska-Białek, A., 477
Póka, R., 27
Polis, C., 59
Pun, T.C., 247
Pymar, H.C., 145

Qiu, Y., 497

Rabinerson, D., 289
Ranta, S., 137
Rashad, H., 121
Rauramo, I., 407
Raviele, K., 9
Raymond, E., 79, 367
Rechberger, T., 477
Reddy, K.V.R., 333
Reid, R.L., 31
Revel, A., 151
Reyes, V., 137
Robbins, L.A., 367
Rodrigues De Lima, G., 395
Romo, L.F., 219, 227
Rosenthal, A.D., 251
Roy, R., 379

Sanchez-Ramos, L., 267
Schaff, E., 171
Schaffer, K., 59
Scharnagl, H., 105
Schechter, J., 137
Schiavon, R., 339
Schmidt, W., 179
Schneider, M., 9
Schochet, T., 133
Scholes, D., 99
Schwartz, J., 263
Seaman, P., 361
Segars, A., 219
Sergerie, M., 425
Shafiq, N., 71
Sheffer-Mimouni, G., 84
Sheiner, E., 289
Shields, W.C., 1, 87, 177, 261, 345, 433
Shochet, T., 301
Shu, X.-O., 251
Simon, M.S., 353
Sinai, I., 201
Sipka, S., 27
Sivin, I., 137, 259
Skorupski, P., 477
Smit, J., 3
Sokal, D.C., 317, 401
Song, L., 207
Sonnenberg, F.A., 447
Speroff, L., 447
Speroff, T., 447
Spirtas, R., 353
Spruyt, A., 367
Srivastava, S., 379
Steiner, M.J., 79
Stewart, F. H., 1, 77, 87, 177, 261, 345, 433
Stirling, A., 301
Strom, B.L., 353
Sucak, A., 279
Suhonen, S., 407
Suthipongse, W., 23

Taneepanichskul, S., 23, 489
Taylor, D., 79
Teichmann, A.T., 105
Tejeda, A.S., 137
Templeton, A., 51
Tomaszewski, J., 477
Travers, E., 137
Trussell, J., 79, 157
Tugrul, S., 323
Tuppurainen, M., 389
Tydén, T., 309
Tyrer, A., 133

Ulmann, A., 83
Ursin, G., 353

Vad, S., 27
Vallejo, M.C., 145
van den Heuvel, M.W., 129
Veldhuis, H.M., 283
Venhola, M., 389
Verhoeven, C.H.J., 129, 197
Vos, A.A.G., 283

Wagaarachchi, P.T., 51
Waldman, L.J., 43
Walker, J., 361
Wang, L., 207
Wang, S.-M., 497
Wang, Y.-L., 505
Weaver, K., 301
Webb, A., 133, 301
Weber, A.L., 353
Weiner, D.H., 263
Weiss, L.K., 353
Weitz, T.A., 77
Westerling, R., 309
Whittington, W.L.H., 241
Wiebe, E.R., 493
Wiegratz, I., 37
Wieland, H., 105
Wildemeersch, D., 207, 501, 513
Winikoff, B., 63, 157
Winkler, U.H., 469
Wu, E., 137
Wu, Z.H., 227
Wyke, S., 361
Xu, H.-X., 251
Xu, Y.-Q., 505

Yagel, S., 151
Yang, D.-T., 497
Yang, G., 251
Yavuzer, B., 323
Yildirim, G., 323

Zhang, W., 207
Zhang, Z., 207
Zhao, X., 207
Zhao, X.-F., 505
Zheng, W., 251
Ziebland, S., 361
Zimmermann, T., 37
Živanović, A., 327

ELSEVIER

Contraception

Contraception 69 (2004) 521–524

Subject Index
Volume 69
January–June 2004

Abortion procedures, attitudes of nurses, 5
Abortion rates, effect of advanced provision of EC, 361
Acceptability, levonorgestrel-releasing IUS following surgical abortion, 247
Acne,
  effect of ethinylestradiol + desogestrel, 469
  effect of ethinylestradiol + levonorgestrel, 469
Adolescent sexuality, ARHP editorial, 245
Advanced provision of EC,
  among women with STD, 241
  effect on abortion rates, 361
Antimycotic co-medication, interaction with ethinylestradiol + etonogestrel, 129
Association of Reproductive Health Professions (ARHP) editorial,
  adolescent sexuality, 345
  family planning care: more than contraception, 261
  Federal abortion ban, 433
  making research matter, 87
  presenting health risks honestly, 177
  reproductive health care, 1
Attitudes, long-cycle OC regimen, 37

Barrier and rhythm contraceptive methods, perceptions and experiences, 493
Bleeding patterns, effect of hormonal EC, 133
Blood flow, following tubal ligation by Pomeroy technique, 151
Bone mineral density,
  effect of DMPA, 99
  effect of ethinylestradiol + levonorgestrel, 179
Breast cancer risk, effect of progestin-only contraceptives, 353

Cervical cancer and OCs, 347
Cervical cytology, effect of progestagen-only contraceptives, 121
Cervical mucus self-monitoring, determination of fertile phase, 9
Cervical priming, sublingual vs. oral misoprostol, 165
Clearplan Easy Fertility Monitor™, determination of fertile phase, 9
Clinical performance,
  ethinylestradiol + desogestrel, 407
  levonorgestrel-releasing IUS, 407
Clinical trial,
  diaphragms, 263
  Nestorone-releasing rod implant, 137
Contraceptive counseling,
  application of motivational interviewing, 213
  effect on post-abortion contraceptive use, 481
role of male partner, 419
Contraceptive efficacy,
  Emetine ditartrate (rodents), 379
  impact of compliance with transdermal system, 189
  nisin (rat, rabbit, monkey, human), 333
Contraceptive methods, costs and net health effects, 447
Contraceptive practices, sociocultural and religious influences, 219
Cost-benefit analysis, contraceptive methods, 447
Costs and net health effects, contraceptive methods, 447
Counseling,
effect on contraceptive use, 481
effect on OC knowledge, 31
Cycle control,
  effect of ethinylestradiol + desogestrel, 469
  effect of ethinylestradiol + levonorgestrel, 469
Cyclo-oxygenase inhibitors, effect on implantation and gestation (rat), 71

Depot medroxyprogesterone acetate (DMPA)
  effect on bone mineral density, 99
  levels of medroxyprogesterone acetate, 3
Diabetes risk, effect of OC use, 251
Diaphragms,
  clinical trials, 263
  sizing methods, 263
Discontinuations, Norplant use, 323
DMPA (depot medroxyprogesterone acetate)

EC (emergency contraception)
EC pills,
  knowledge and misconceptions, 227
  repeat use, 339
EC pills access, telephone prescription service, 367
EC pills over-the-counter, women's knowledge, attitudes and practices, 309
Ectopic pregnancies, levonorgestrel EC, 83
Efficacy and acceptability, GyneFix 200 IUS, 207
Emergency contraception (EC),
  advanced provision among women with STD, 241
  effect of advanced provision, 361
  ethinylestradiol + levonorgestrel, 133, 301
  ethinylestradiol + norethindrone, 133, 301
  levonorgestrel, 79, 373
mifepristone, 373
prescribing practices, 43
Emetine ditartrate, contraceptive efficacy (rodents), 379

0010-7824/04/$ – see front matter © 2004 Elsevier Inc. All rights reserved.

Erythromycin, use for nonsurgical female sterilization, 47
Ethinylestradiol + desogestrel,
clinical performance, 407
effect on cycle control, quality of life, acne, 469
effect on lipid profile, 271
effect on serum resistin levels, 477
Ethinylestradiol + dienogest, use in long-cycle regimen, 37
Ethinylestradiol + drospirenone,
clinical study, 23
effect on lipid profile, 271
Ethinylestradiol + etonogestrel, effect on lipid metabolism, 389
Ethinylestradiol + gestodene,
effect on serum resistin levels, 477
effect on sexual behavior, 237
mutagenic effect, 327
Ethinylestradiol + levonorgestrel,
clinical study, 23
effect on bone mineral density, 279
effect on cycle control, quality of life, acne, 469
effect on hemostatic variables, 461
effect on lipid metabolism, 389
effect on lipoprotein metabolism, 205
Ethinylestradiol + levonorgestrel EC,
effect on bleeding patterns, 133
side effects, 301
Ethinylestradiol + norethindrone, effect on risk of diabetes, 251
Ethinylestradiol + norethindrone EC,
effect on bleeding patterns, 133
side effects, 301
Ethinylestradiol + norgestrel, effect on lipid profile, 395
Experiences of married and unmarried women, medical abortion, 63
Extended OC cycles, attitudes, 37

Factor V Leiden carriers, effect of OC use, 27
Failure rates and consequences, use of periodic abstinence, 15
Family planning, lactational amenorrhea method, 317
Family planning care: more than contraception, ARHP editorial, 261
Federal abortion ban, ARHP editorial, 433
Family planning referral among women with STD, 241
Female sterilization,
Falope rings, vs. Filshie clips, 145
Filshie clips vs. Pomeroy technique, 267
tubal ligation by Pomeroy technique, 151
use of erythromycin, 47
Fertile phase determination,
monitoring cervical mucus, 9
use of electronic device, 9
Fertility restoration, vasectomized men, 497
FibroPlant™-LNG IUS, removal force measurement, 513
Filshie clips vs. Falope rings, postoperative pain following tubal sterilization, 145
Filshie clips vs. Pomeroy technique, obstetric tubal sterilization, 247

General practitioners, role in IUD use, 283
Gestation, effect of cyclo-oxygenase inhibitors (rat), 71
GyneFix® 200, frameless, copper intrauterine system, 207
GyneFix® 200 IUS, efficacy and acceptability, 207
GyneFix® IUS, removal force measurement, 501, 513

Hazard analysis, medical abortion trials, 157
Health effects and costs, contraceptive methods, 447
Hemostatic variables,
effect of ethinylestradiol + etonogestrel, 461
effect of ethinylestradiol + levonorgestrel, 461
High blood pressure and progestogen-only pills, review, 89
History of IUDs, pre-1960 to new century, 437

Implanon use, women older than 35 years, 489
Implant contraceptive,
etonogestrel, 489
levonorgestrel, 323
Nestorone-releasing, 137
Implantation, effect of cyclo-oxygenase inhibitors (rat), 71
Injectable contraceptive,
depot medroxyprogesterone acetate, 3, 99
medroxyprogesterone acetate + estradiol cypionate, 115
norethisterone enanthate, 115
Intrauterine device (IUD),
clinical outcomes of postplacental insertion, 279
effects on pregnancy evolution and fetus, 343
TCu 380A, 279
Intrauterine devices, history in the U.S., 437
Intrauterine system (IUS),
GyneFix, 501, 513
GyneFix 200, 207
levonorgestrel-releasing, 247, 289, 407
Ipas™ manual vacuum aspiration syringe, compatible cannulae, 171
IUD (intrauterine device)
IUD performance, nulliparous women, 249
IUD use, role of general practitioners, 283
IUDs and reproductive health, 437
IUS (intrauterine system)

Knowledge, attitudes and practices, EC pills over-the-counter, 309
Knowledge and effect of counseling, oral contraceptives, 31

Lactational amenorrhea, method of family planning, 317
Levonorgestrel, effect on ovarian function, 373
Levonorgestrel EC,
ectopic pregnancies, 83
minimum effectiveness, 79
Levonorgestrel-releasing IUS,
acceptability, 247
clinical performance, 407
diagnosis and therapy of lost device, 289
Lipid profile,
effect of ethinylestradiol + desogestrel, 271
effect of ethinylestradiol + drospirenone, 271
effect of ethinylestradiol + norgestrel, 395
effect of injectable contraceptives, 115

Lipoprotein metabolism, effect of ethinylestradiol + levonorgestrel, 105
Long-cycle OC regimen, attitudes, 37
Lost levonorgestrel-releasing IUS, diagnosis and therapy, 289

Making research matter, ARHP editorial, 87
Male partner, role in post-abortion contraception counseling, 419
Medical abortion,
  experience in developing countries, 63
  mifepristone + misoprostol, 51, 63
  outcome of midtrimester terminations, 51
Medical abortion trials, hazard analysis, 157
Medical" and "surgical: abortion, rethinking the modifiers, 77
Medroxyprogesterone acetate, serum levels among DMPA users, 3
Medroxyprogesterone acetate + estradiol cypionate, effect on menstrual pattern and lipid profiles, 115
Menstrual pattern, effect of injectable contraceptives, 115
Midtrimester medical abortion, review of cases, 51
Mifepristone,
  effect on ovarian function, 373
  presenting health risks, ARHP editorial, 177
Mifepristone + misoprostol,
  experiences in developing country, 63
  midtrimester terminations, 51
Minimum effectiveness, levonorgestrel EC, 79
Misconceptions and knowledge, effect on acceptance of EC pills, 227
Misoprostol, sublingual vs. oral for cervical priming, 165
Motivational interviewing, use in contraceptive counseling, 213
Mutagenic effect, ethinylestradiol + gestodene, 327

Nestorone, effect on pituitary gonadotropic cells (rat), 505
Nestorone®-releasing rod implant, clinical trial, 137
Nisin,
  anti-microbial peptide, 333
  contraceptive efficacy (rat, rabbit, monkey, human), 333
  effect on sperm motility (rat, rabbit, monkey, human), 333
Norethisterone enanthate, effect on menstrual pattern and lipid profiles, 115
Norplant, side effects and reasons for discontinuation, 323
Nulliparous women, clinical performance of IUDs, 259
Nurses' attitudes, abortion procedures, 59
NuvaRing®,
  effect of antimycotic co-medication, 129
  effect of tampon co-usage, 197
  effect on hemostatic variables, 461
  effect on lipid metabolism, 389
  vaginal ring releasing ethinylestradiol + etonogestrel, 129, 187, 389, 461

OC (oral contraceptive)
OC compliance, effect of postpartum educational intervention, 413
OC pills over-the-counter, screening by pharmacy workers, 295
OC use,
  effect in factor V Leiden carriers, 27
  risk of diabetes, 251
OCs and cervical cancer, 347
Older women,
effect of triphasic combined OC on lipid profile, 395
Implanon implant use, 489
Oral contraceptive (OC),
  ethinylestradiol + desogestrel, 271, 407, 469, 477
  ethinylestradiol + dienogest, 37
  ethinylestradiol + drosopirenone, 23, 271
  ethinylestradiol + gestodene, 237, 327, 477
  ethinylestradiol + levonorgestrel, 23, 105, 179, 389, 461, 469
  ethinylestradiol + norethindrone, 251
  knowledge and effect of counseling, 31
  progestogen-only pills, 89
  triphasic ethinylestradiol + norgestrel, 395
Ortho Evra®, weekly contraceptive transdermal system, 189
Ovarian function,
  effect of levonorgestrel, 373
  effect of mifepristone, 373
Ovarian morphology, following tubal ligation by Pomeroy technique, 151
Over-the-counter EC pills, women's knowledge, attitudes and practice, 309
Over-the-counter OC pills, screening by pharmacy workers, 295

Perceptions and experiences, barrier and rhythm contraceptive methods, 493
Periodic abstinence,
  failure rates and consequences, 15
  use in developing countries, 15
Pharmacy workers, screening for over-the-counter OC pills, 295
Pituitary gonadotropic cells, effect of Nestorone (rat), 505
Pomeroy technique tubal ligation, effect on ovarian morphology and blood flow, 151
Pomeroy technique vs. Filshie clips, obstetric tubal sterilization, 267
Post-abortion contraception counseling, role of male partner, 419
Post-abortion contraceptive use, effect of pre-abortion counseling, 481
Postoperative pain following tubal sterilization, Filshie clips vs. Falope rings, 145
Postpartum educational intervention, effect on OC compliance, 413
Postplacental IUD insertion, clinical outcomes, 279
Pre-abortion counseling, effect on post-abortion contraceptive use, 481
Pregnancy despite IUD, 343
Pregnancy rates after vasectomy, 401
Prescribing practices, emergency contraception, 43
Presenting health risks honestly, ARHP editorial, 177
Progestagen-only contraceptives, effect on cervical cytology, 121
Progestin-only contraceptives, effect on risk of breast cancer, 353

Progestogen-only pills and high blood pressure, review, 89

Quality of life,
effect of ethinylestradiol + desogestrel, 469
effect of ethinylestradiol + levonorgestrel, 469

Religious and sociocultural influences, effect on contraceptive practices, 219
Removal force measurement,
FibroPlant™-LNG IUS, 513
GyneFix IUD, 501, 513
Repeat use, EC pills, 339
Reproductive health and IUDs, 437
Reproductive health care, ARHP editorial, 1
Resistin levels,
effect of ethinylestradiol + desogestrel, 477
effect of ethinylestradiol + gestodene, 477
Restoration of fertility, vasectomized men, 497
Rhythm and barrier contraceptive methods, perceptions and experiences, 493

Screening and monitoring procedures, Standard Days Method users, 201
Sexual behavior, effect of ethinylestradiol + gestodene, 237
Side effects,
ethinylestradiol + levonorgestrel EC, 301
ethinylestradiol + norethindrone EC, 301
Norplant use, 323
Sociocultural and religious influences, effect on contraceptive practices, 219
Sperm motility, effect of nisin (rat, rabbit, monkey, human), 333
Spermatozoa, effect of tetradecyl-dimenthl-benzyl ammonium fluoride, 425
Standard Days Method™, importance of screening and monitoring, 201
STD (sexually transmitted diseases)
Sublingual vs. oral misoprostol, effect on cervical priming, 165
"Surgical" and "medical" abortion, rethinking the modifiers, 77

Tampon co-usage, interaction with ethinylestradiol + etonogestrel, 197
TC 380A, clinical outcomes of postplacental insertion, 279
Telephone access to EC pills, 367
Tetradecyl-dimethyl-benzyl ammonium fluoride, effect on spermatozoa, 425
Transdermal contraceptive system,
impact of compliance on contraceptive efficacy, 189
Ortho Evra, 189
Tubal occlusion, Falope rings vs. Filshie clips, 145

Urologists survey, pregnancy rate after vasectomy, 401

Vacuum aspiration,
Ipas double-valve manual syringe, 171
sublingual vs. oral misoprostol for cervical priming, 165
Vaginal ring, NuvaRing, 129, 197, 389
Vasectomized men, restoration of fertility, 497
Vasectomy, pregnancy incidence following procedure, 401

Women treated for STD, family planning referral and advanced provision of EC, 241